Clinical Trials Logo

Rhinoconjunctivitis clinical trials

View clinical trials related to Rhinoconjunctivitis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05560698 Recruiting - Rhinoconjunctivitis Clinical Trials

A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

The motivation-enhancing intervention is designed for participants in the ILIT.NU trial. The participants are patients with hay fever who are treated with a vaccination in an inguinal lymph node. The motivation-enhancing intervention is a web-based app developed in collaboration with patient partners and is intended to increase retention and reporting in the ILIT.NU trial.

NCT ID: NCT04898283 Recruiting - Rhinoconjunctivitis Clinical Trials

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Start date: May 31, 2021
Phase: Phase 3
Study type: Interventional

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.

NCT ID: NCT04891237 Recruiting - Rhinoconjunctivitis Clinical Trials

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Start date: June 14, 2021
Phase: Phase 3
Study type: Interventional

Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive

NCT ID: NCT04435990 Recruiting - Rhinoconjunctivitis Clinical Trials

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

MM09-SIT-023
Start date: October 6, 2020
Phase: Phase 3
Study type: Interventional

A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with mild to moderate asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.